View Older Stories View More Recent Stories
-
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
-
AavantiBio and Resilience Announce Strategic Collaboration for Gene Therapy Development and Manufacturing
-
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility (RACA)
-
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
-
Form SC 13G KalVista Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
-
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
-
DTx Pharma to Participate in Upcoming Virtual Investor Conferences
-
Eliem Therapeutics Announces $60 Million Series B Financing
-
Larimar Therapeutics (LRMR) Announces $95 Million Private Placement Financing of Common Stock, Warrants
-
Larimar Therapeutics Announces $95 Million Private Placement Financing
-
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Form SC 13G/A FIVE PRIME THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Lyra Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Pandion Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Inhibrx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
AavantiBio Rounds Out Leadership Team with Appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer
-
Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update
-
Form SC 13D Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Seres Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Affinia Therapeutics Closes $110 Million Series B Financing
-
Chardan Acts as Exclusive Placement Agent in Forge Biologics' $120 Million Series B Financing
-
Ceribell Announces Completion Of $53 Million Series C Financing
-
Forge Biologics Announces Closing of $120 Million Series B Financing
-
Novo Seeds co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
-
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
-
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
-
Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)
-
AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
-
Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
-
PepGen to Present a CureDuchenne Webinar on Unlocking the Potential of Exon Skipping Therapeutics for Duchenne Muscular Dystrophy
-
Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19
-
Form SC 13D Achilles Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
-
Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies
-
AavantiBio Deepens AAV Manufacturing Capabilities with Key Hires to Support Strategic Growth
-
Antios Therapeutics Raises $96 Million in a Series B Financing
-
Ventus Therapeutics Closes $100 Million Series B Financing
-
Form SC 13G/A Trillium Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Atea Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Bolt Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
DTx Pharma to Participate in the 2021 Needham Virtual Healthcare Conference
-
Metagenomi Extends Series A Financing from RA Capital and Welcomes Andrew Levin to Its Board of Directors
-
Nucleix Secures $55 Million Funding Led by RA Capital Management and Additional Prominent Life Science Investors to Advance Lung EpiCheck® for Early Detection of Lung Cancer
-
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials
-
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
-
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
-
Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines
-
New Equilibrium Bio raises $10M from RA Capital for AI-powered quantum chemistry
-
Form SC 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

